Hemnes Anna, Rothman Alexander M K, Swift Andrew J, Zisman Lawrence S
Vanderbilt University Medical Center, Nashville, TN, USA.
University of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Pulm Circ. 2020 Nov 18;10(4):2045894020957234. doi: 10.1177/2045894020957234. eCollection 2020 Oct-Dec.
Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, proteomic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomography. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions. Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of pulmonary arterial hypertension.
肺动脉高压是一种复杂的疾病,由无数生物和环境过程相互作用导致肺血管重塑,进而引发肺动脉高压。尽管目前有可用的治疗方法,但该疾病的发病率和死亡率仍然很高。人们对识别和应用生物标志物以帮助诊断肺动脉高压患者、提供预后信息、指导治疗以及作为替代终点非常感兴趣。关于潜在生物标志物候选物的文献很多,但在肺动脉高压临床应用中实施生物标志物存在重大障碍。已经采用了各种组学策略来识别肺动脉高压中受调控的关键途径,这些途径可作为生物标志物,包括基因组学、转录组学、蛋白质组学和代谢组学方法。其他生物学相关成分,如循环细胞、微小RNA、外泌体和游离DNA,最近也越来越受到关注。由于这些组学方法产生的数据集规模及其复杂性,人工智能方法正越来越多地被用于解读其意义。人们越来越有兴趣用各种方式对肺部进行成像,以了解和可视化导致肺血管重塑的肺部过程,包括高分辨率计算机断层扫描、氙磁共振成像和正电子发射断层扫描。这种成像方式有可能显示治疗干预导致的疾病改善。由于右心室功能是预后的主要决定因素,用超声心动图或心脏磁共振成像对右心室进行成像在评估患者中起着重要作用,在肺动脉高压的临床研究中也可能有用。